Increasing CSF phospho-tau levels during cognitive decline and progression to dementia.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Neurobiology of Aging

• Publication date

  2008-10-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1016/J.NEUROBIOLAGING.2007.03.027PMID 17512092
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics

  2009cited by this paper
• Differential CSF biomarker levels in APOE-epsilon4-positive and -negative patients with memory impairment.

  2007cited by this paper
• Identifying Patients at High and Low Risk of Cognitive Decline Using Rey Auditory Verbal Learning Test among Middle-Aged Memory Clinic Outpatients

  2006cited by this paper
• Differential CSF Biomarker Levels in APOE-ε4-Positive and -Negative Patients with Memory Impairment

  2006cited by this paper
• Ten-year risk of dementia in subjects with mild cognitive impairment

  2006cited by this paper
• Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.

  2006cited by this paper
• Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology.

  2006cited by this paper
• Temporal Profile of Amyloid-β (Aβ) Oligomerization in an in Vivo Model of Alzheimer Disease

  2006cited by this paper
• Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the Consortium on DLB International Workshop

  2006cited by this paper
• Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment.

  2006cited by this paper
• The CSF levels of total-tau and phosphotau in patients with relapsing-remitting multiple sclerosis

  2006cited by this paper
• Follow-up investigations in cerebrospinal fluid of patients with dementia with Lewy bodies and Alzheimer’s disease

  2005cited by this paper
• Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer’s disease?

  2005cited by this paper
• Longitudinal changes in cognition and behavior in asymptomatic carriers of the APOE e4 allele

  2004cited by this paper
• CSF biomarkers for mild cognitive impairment

  2004cited by this paper
• Is MCI really just early dementia? A systematic review of conversion studies

  2004cited by this paper
• Context-specific memory and apolipoprotein E (ApoE) ε4: Cognitive evidence from the NIMH prospective study of risk for Alzheimer's disease

  2004cited by this paper
• Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment

  2004cited by this paper
• Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease.

  2003cited by this paper
• CSF markers for pathogenic processes in Alzheimer's disease: diagnostic implications and use in clinical neurochemistry.

  2003cited by this paper
• Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients.

  2003cited by this paper
• Mild cognitive impairment: experience from a memory clinic

  2003cited by this paper
• Neuropsychological features of mild cognitive impairment and preclinical Alzheimer's disease

  2003cited by this paper
• Rey verbal learning test is a useful tool for differential diagnosis in the preclinical phase of Alzheimer's disease: comparison with mild cognitive impairment and normal aging

  2003cited by this paper
• The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics

  2002cited by this paper
• Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice.

  2001cited by this paper
• Current concepts in mild cognitive impairment.

  2001cited by this paper
• Boston Naming Test

  2001cited by this paper
• Three-year follow-up of cerebrospinal fluid tau, beta-amyloid 42 and 40 concentrations in Alzheimer's disease.

  2000cited by this paper
• Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization.

  2000cited by this paper
• Apolipoprotein E4 accelerates dementia and increases cerebrospinal fluid tau levels in Alzheimer's disease.

  1999cited by this paper
• Mild Cognitive Impairment Clinical Characterization and Outcome

  1999cited by this paper
• Longitudinal stability of CSF tau levels in Alzheimer patients.

  1999cited by this paper
• Longitudinal study of cerebrospinal fluid levels of tau, Aβ1–40, and Aβ1–42(43) in Alzheimer's disease: A study in Japan

  1998cited by this paper
• Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer’s disease: a community based follow up study

  1998cited by this paper
• Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan.

  1998cited by this paper
• Frontotemporal lobar degeneration

  1998cited by this paper
• Beyond attention: The role of amygdala NMDA receptors in fear conditioning

  1997cited by this paper
• Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB)

  1996cited by this paper
• Increasing cerebrospinal fluid tau levels in a subgroup of Alzheimer patients with apolipoprotein E allele epsilon 4 during 14 months follow-up.

  1996cited by this paper
• Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?

  1995cited by this paper
• Episodic memory functioning in a community-based sample of old adults with major depression: utilization of cognitive support.

  1994cited by this paper
• Wechsler memory scale-revised

  1988cited by this paper
• Clinical diagnosis of Alzheimer's disease

  1984cited by this paper
• WAIS-R manual : Wechsler adult intelligence scale-revised

  1981cited by this paper
• “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician

  1975cited by this paper

• Molecular pathways and biomarkers associated with age-related cognitive decline

  2025cites this paper
• A genome-wide association study of longitudinal change in CSF tau among non-demented elderly.

  2024cites this paper
• Brain Age Estimation on a Dementia Cohort Using FLAIR MRI Biomarkers

  2023cites this paper
• Detecting conversion from mild cognitive impairment to Alzheimer’s disease using FLAIR MRI biomarkers

  2023cites this paper
• TREM2, Microglia, and Alzheimer's Disease.

  2021cites this paper
• Can the RAVLT predict deterioration from MCI to dementia? Data from long term follow up

  2021cites this paper
• Role of triggering receptor expressed on myeloid cells 2 (TREM2) in neurodegenerative dementias

  2021cites this paper
• Obstructive sleep apnea and Alzheimer's disease-related cerebrospinal fluid biomarkers in mild cognitive impairment.

  2020cites this paper
• Potential Bidirectional Relationship Between Periodontitis and Alzheimer’s Disease

  2020cites this paper
• Bridging the Gap Between Fluid Biomarkers for Alzheimer’s Disease, Model Systems, and Patients

  2020cites this paper
• Relevance of the interplay between amyloid and tau for cognitive impairment in early Alzheimer's disease.

  2019cites this paper
• Correlations Between Cerebrospinal Fluid Biomarkers Concentration and Severity of Cognitive Impairment in Alzheimer Disease

  2019cites this paper
• Diagnosis of Alzheimer’s disease utilizing amyloid and tau as fluid biomarkers

  2019cites this paper
• Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study

  2019cites this paper
• New insights into the role of TREM2 in Alzheimer’s disease

  2018cites this paper
• Genome-wide association study identifies four novel loci associated with Alzheimer’s endophenotypes and disease modifiers

  2017cites this paper
• Genome-wide association study identifies four novel loci associated with Alzheimer's endophenotypes and disease modifiers.

  2017cites this paper
• A Pilot Longitudinal Study on Cerebrospinal Fluid (CSF) Tau Protein in Alzheimer's Disease and Vascular Dementia.

  2016cites this paper
• Anti-Correlated Cerebrospinal Fluid Biomarker Trajectories in Preclinical Alzheimer's Disease.

  2016cites this paper
• [Alzheimer's disease and Helicobacter pylori infection: a possible link?].

  2016cites this paper
• Variations in the FRA10AC1 Fragile Site and 15q21 Are Associated with Cerebrospinal Fluid Aβ1-42 Level

  2015cites this paper
• The Role of TREM2 in Alzheimer’s Disease and Other Neurological Disorders

  2014cites this paper
• Variants in PPP3R1 and MAPT are associated with more rapid functional decline in Alzheimer's disease: The Cache County Dementia Progression Study

  2014cites this paper
• Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).

  2014cites this paper
• The Innate Immune System in Alzheimer's Disease

  2013cites this paper
• GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease.

  2013cites this paper
• Fluid biomarkers for diagnosing dementia: rationale and the Canadian Consensus on Diagnosis and Treatment of Dementia recommendations for Canadian physicians

  2013cites this paper
• Biomarkers as Monitors of Drug Effect, Diagnostic Tools and Predictors of Deterioration Rate in Alzheimer’s Disease

  2013cites this paper
• Research Article Variants in PPP3R1 and MAPTare associated with more rapid functional decline inAlzheimer's disease: TheCache County Dementia Progression Study

  2013cites this paper
• Biomarqueurs du liquide cérébrospinal dans la maladie d’Alzheimer

  2013cites this paper
• Impact of chronic Helicobacter pylori infection on Alzheimer's disease: preliminary results.

  2012cites this paper
• Cerebrospinal Fluid Proteins Predict Longitudinal Hippocampal Degeneration in Early-stage Dementia of the Alzheimer Type

  2012cites this paper
• Neuropsychological predictors of the outcome in non-demented subjects with cognitive complaints

  2012cites this paper
• Hourly variability of cerebrospinal fluid biomarkers in Alzheimer's disease subjects and healthy older volunteers.

  2012cites this paper
• Fluid biomarkers for diagnosing dementia : rationale and recommendations for Canadian Physicians

  2012cites this paper
• Identification of Novel Fluid Biomarkers for Alzheimer's Disease

  2012cites this paper
• The effect of apolipoprotein E (ApoE) genotype on biomarkers of amyloidogenesis, tau pathology and neurodegeneration in Alzheimer's disease

  2011cites this paper
• Antipsychotic medication is associated with selective alterations in ventricular cerebrospinal fluid Aβ 40 and tau in patients with intractable unipolar depression

  2011cites this paper
• Disease Tracking Markers for Alzheimer's Disease at the Prodromal (MCI) Stage

  2011cites this paper
• New Tools for the Study of Alzheimer’s Disease

  2011cites this paper
• Longitudinal Changes of CSF Biomarkers in Alzheimer's Disease

  2011influential citation
• Disease specific cerebrospinal fluid investigations

  2011cites this paper
• si-RNA inhibition of brain insulin or insulin-like growth factor receptors causes developmental cerebellar abnormalities: relevance to fetal alcohol spectrum disorder

  2011cites this paper
• Complement 3 and factor h in human cerebrospinal fluid in Parkinson's disease, Alzheimer's disease, and multiple-system atrophy.

  2011cites this paper
• [Dementia: progress in diagnosis and treatment; Topics; V. Recent topics; 1. Biomarkers for Alzheimer's disease and other dementia].

  2011cites this paper
• Multiplexed Immunoassay Panel Identifies Novel CSF Biomarkers for Alzheimer's Disease Diagnosis and Prognosis

  2011cites this paper
• Added diagnostic value of CSF biomarkers in differential dementia diagnosis.

  2010cites this paper
• Serial MRI and CSF biomarkers in normal aging, MCI, and AD

  2010cites this paper
• CSF phospho-tau correlates with behavioural decline and brain insoluble phospho-tau levels in a rat model of tauopathy

  2010cites this paper
• Kognitiv funktion och biomarkörer för demens - en jämförande studie från en minnesmottagning

  2010cites this paper
• Brain perfusion SPECT correlates with CSF biomarkers in Alzheimer’s disease

  2010cites this paper
• Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people.

  2010cites this paper
• Effects of Omega-3 Fatty Acids on Inflammatory Markers in Cerebrospinal Fluid and Plasma in Alzheimer’s Disease: The OmegAD Study

  2009cites this paper
• Use of biomarkers to select the target population for clinical trials in subjects with mild cognitive impairment

  2009cites this paper
• Meta-analysis of CSF and MRI biomarkers for detecting preclinical Alzheimer's disease

  2009cites this paper
• Neurodegenerative Biomarkers in Healthy Elderly - with special reference to the preclinical pattern of biological and cognitive markers for Alzheimer’s disease

  2009cites this paper
• Investigating the mechanism of action of Colostrinin™ on cells in culture

  2009cites this paper
• Proteomics-derived cerebrospinal fluid markers of autopsy-confirmed Alzheimer’s disease

  2009cites this paper
• Knowing the natural course of biomarkers in AD: Longitudinal MRI, CSF and PET data

  2009cites this paper
• EFNS guidelines on disease‐specific CSF investigations

  2009cites this paper
• Alzheimer's Disease Neuroimaging Initiative

  2008cites this paper
• Tau as a biomarker of neurodegenerative diseases.

  2008cites this paper
• Biomarkers for early diagnosis of Alzheimer disease: ‘ALZheimer ASsociated gene’– a new blood biomarker?

  2008cites this paper
• ALZHEIMER'S DISEASE AND DEMENTIA WITH LEWY BODIES: SPECIAL FOCUS ON THE ROLE OF SERPINS

  2007cites this paper